Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
OM1
Real-world data and outcomes platform with condition-specific registries and AI-driven patient phenotyping.
OM1, founded in 2015 and headquartered in Boston, Massachusetts, builds longitudinal real-world data networks and condition-specific registries, with AI models for patient identification and outcome analysis used in evidence generation and commercial analytics. The company announced an $85 million financing round in 2021. No vendor-held security certifications were found on its public site; model performance in your indication should be validated as part of any evaluation.
- Headquarters
- Boston, United States
- Founded
- 2015
- Deployment options
- cloud
- Website
- https://www.om1.com
- https://www.linkedin.com/company/om1-inc
Categories
AI Use Cases
- Patient Identification & Segmentation
Vendor Scorecard
50% — Partial coverage. Coverage score — how completely Atlas documents OM1 across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Not documented by Atlas
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Implementation & Onboarding — Not documented by Atlas
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Commercial, Medical Affairs, Data Management
Solution Scope — Documented
Real-World Evidence
Company Viability — Partially documented
Private, Founded 2015
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Clinical Trial Activity
3 registered trials where OM1 is the lead sponsor. Source: ClinicalTrials.gov, verified 2026-07-29.
Top conditions studied: Dysthymia, Major Depression, Alopecia Areata, Atopic Dermatitis, Dermatology
- A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions (NCT05084417, unknown)
- Implementation of Harmonized Depression Outcome Measures in a Health System (NCT04235712, completed)
- Implementation of Harmonized Depression Outcome Measures in a Primary Care Registry and a Mental Health Registry (NCT04235725, completed)
Questions to Ask This Vendor
- Which condition registries cover our indication, and how deep is the longitudinal history?
- How is phenotyping model performance validated and reported?
- What security certifications does the company hold?
- How can registry data support our specific evidence-generation plan?